Myriad Genetics (NASDAQ:MYGN) is a healthcare company that specializes in genetic testing and precision medicine. The firm focuses on providing tests that assess an individual’s risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad Genetics operates in several key areas, including hereditary cancer, urology, dermatology, autoimmune diseases, and mental health, striving to deliver actionable insights to both patients and healthcare providers. Their objective is to enhance patient outcomes by integrating genetic insights into healthcare decision-making, promoting a more personalized approach to treatment and preventive care. Through its comprehensive suite of tests, Myriad Genetics aims to empower individuals with valuable health information to make informed decisions about their health and lifestyle, driving forward the evolution of personalized medicine.